The medication is commonly used in situations involving certain distressing symptoms in the upper respiratory tract. It is applied across domains where additional symptomatic support is needed, and the primary role is providing supportive symptom management.

Symptomatic Management and Therapeutic Domains

The combination is applicable within clinical settings that involve acute or disruptive symptom patterns, such as the common cold and acute upper respiratory infections. It is commonly used to help with symptom clusters that may become intense or disruptive, specifically to help with both nasal congestion (stuffy nose) and related symptoms of runny nose (rhinorrhea) and frequent sneezing. The medication is relevant for easing conditions presenting with systemic or localized discomfort, including allergic rhinitis (seasonal hay fever and perennial allergies) and associated sinus congestion.

“The medication provides supportive relief when symptoms interfere with routine activities, helping patients cope more steadily with symptom fluctuations.”

This supportive assistance helps ease the overall symptom load and contributes to day-to-day comfort during symptomatic periods. The sustained-release format is applied in scenarios where additional management of discomfort is required for complex symptom profiles, supporting the patient during difficult episodes by easing distress for prolonged symptomatic periods.

Quick Fact: Supportive Management of Simultaneous Congestion and Rhinorrhea (The combination may assist with symptoms where nasal obstruction and excessive fluid discharge occur together).

Regulatory References

1. NIH MedlinePlus overview

The official regulatory eligibility profile for this medicine is defined by absolute prohibitions and specific population constraints. In several jurisdictions (e.g., US, Canada), the regulatory withdrawal of Phenylpropanolamine (PPA) renders the product non-eligible for all populations.

Populations for whom use is contraindicated include patients with severe or uncontrolled hypertension, coronary disease, or hyperthyroidism. The medicine is strictly prohibited for patients taking Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of stopping this therapy. Contraindications further extend to patients with lower respiratory tract disease and those with difficulty urinating due to prostate enlargement.

Age-related eligibility rules state the medicine is not recommended for children under 6 years of age. Use in older adults (over 65) is designated as restricted due to increased susceptibility to adverse effects.

Condition-specific eligibility rules require conditional use for patients with glaucoma, epilepsy, or underlying hepatic impairment or renal impairment. Regarding pregnancy and lactation, the medicine is officially not recommended unless use is deemed essential by a physician.

Interactions with other medicines and products

The official interaction profile of Колдакт, derived from regulatory labeling, is structured by the combination of its sympathomimetic and antihistamine components.

Prohibited and Restricted Combinations

Interacting Substance	Official Constraint and Outcome
Monoamine Oxidase Inhibitors (MAOIs)	Contraindicated. Must not be used concurrently or within 14 days of discontinuing MAOI therapy due to the risk of severe blood pressure potentiation and intensified anticholinergic effects.
CNS Depressants and Alcohol	Concurrent use should be avoided. The combination causes an additive effect, resulting in significant central nervous system depression.
Antihypertensive Agents	Phenylpropanolamine may formally lessen the therapeutic activity of these medicines, a pharmacodynamic antagonism documented in the labeling.

---

Pharmacokinetic and Pharmacodynamic Interactions

The antihistamine component, Chlorphenamine, is documented to cause a pharmacokinetic interaction by inhibiting the metabolism of Phenytoin, which is officially stated to carry the risk of increased exposure and Phenytoin toxicity. Furthermore, co-administration with other Anticholinergic Drugs or Other Sympathomimetics is noted for the risk of potentiating their respective effects. The regulatory label also includes a population-specific consideration: Elderly and Children are more likely to experience intensified neurological anticholinergic effects than other patient groups.

How Колдакт Works

Chlorphenamine, one of the active agents, functions as an inverse agonist or competitive antagonist at the Histamine H1 receptors located peripherally and centrally. This direct molecular blockade of the histaminergic pathway results in a reduction in capillary permeability and a functional inhibition of glandular secretion at the tissue level, shaping the drug’s fluid dynamics modulation profile.

The second component, Phenylpropanolamine (PPA), acts as an indirect sympathomimetic agent. Its mechanism involves promoting the release of endogenous norepinephrine from presynaptic terminals, which subsequently activates postsynaptic alpha-adrenergic receptors on vascular smooth muscle. This signaling cascade initiates intense, localized vasoconstriction in the nasal lining, leading to a decrease in the volume of blood trapped in the mucosal tissue and a physiological decrease in tissue volume.

This combination utilizes a complementary dual-system mechanism, engaging both H1 antagonism (fluid dynamics modulation) and alpha-adrenergic potentiation (vascular volume modulation) simultaneously. This coordinated activity facilitates the comprehensive physiological adjustment of the upper respiratory tract's state.

The administration of Колдакт is based on its formulation as an oral sustained-release capsule, which governs the required frequency and method of intake. The medicine is taken orally and the capsule must be swallowed whole to preserve the integrity of the long-acting delivery system; it must not be crushed, chewed, or opened. Taking the capsule in any altered form is contrary to the usage protocol. Each dose should be consumed with a full glass of water, and the medication may be taken with or without food.

---

Standard Dosing and Scheduling

Feature	Protocol
Dosing Frequency	One sustained-release capsule twice daily, maintaining a 12-hour interval between doses.
Maximum Dose	The maximum dosage must not exceed two capsules in a 24-hour period.
Course Duration	Use is limited to short-term symptomatic relief, generally not to exceed 7 consecutive days.

---

Specific Population Rules

Administration guidance addresses specific populations. The medicine is generally not recommended for children under 6 years of age. For older adults (geriatric population), a lower initial dose or reduced frequency may be necessary due to potential physiological differences in drug clearance. If a dose is missed, the procedure involves taking it as soon as remembered; however, if it is close to the time for the next scheduled dose, the missed dose should be skipped entirely, and the regular schedule resumed. Double dosing to compensate for a forgotten dose is discouraged.

Research Evidence / Overview of Studies for Колдакт

---

Evidence for Use in Common Cold Symptoms

The research consists of Randomized Controlled Trials (RCTs) and comprehensive systematic literature reviews that analyze data from these trials. These studies were conducted during periods of increased symptom activity and focused on conditions characterized by acute or disruptive episodes, such as the common cold. Researchers examined what change was measured in patient-reported outcomes related to physical discomfort, tracking symptoms like nasal congestion (stuffiness) and rhinorrhea (runny nose).

Findings from aggregated data across these studies suggest patterns related to short-term changes in patient-reported experiences compared to an inactive substance (placebo). Studies monitored symptoms to evaluate the overall burden, reporting patterns in how symptoms evolved within the observed populations during the acute phase of illness. However, the existing evidence quality varies across studies, and certainty remains low in some areas.

Evidence for Use in Allergic Rhinitis

The combination was observed in studies for conditions characterized by fluctuating or episodic manifestations like allergic rhinitis. Research examined how the Chlorphenamine (antihistamine) and Phenylpropanolamine (decongestant) components performed together for managing specific symptoms, including sneezing, fluid symptoms, and nasal congestion. This research contributes to contextualizing how patients reported their experience with concurrent anti-allergic symptoms and stuffiness.

Long-Term Evidence and Follow-up Duration

Research exploring short-term symptom changes for this combination primarily involved trials with limited follow-up durations. The studies monitored how symptoms evolved in patients only for the acute period of a cold or for short cycles of allergic symptoms. There is limited information for long-term outcomes or durability of effect beyond these brief observed time intervals.

Research in Specific Patient Groups

The primary body of evidence examined the combination in adults and older children (generally defined as 12 years and above). Data for use in young children (under 12 years of age) remain insufficient. Data for subgroups related to older adults or individuals with comorbid conditions remain uncertain. Results apply only to the populations studied.

Key Limitations and Areas of Uncertainty

A key limitation is the evidence quality varies across studies. The research includes studies related to the Phenylpropanolamine (PPA) component that are historic, as the regulatory context for PPA has changed in some jurisdictions. Finally, the evidence base includes a reliance on patient-reported outcomes describing perceived discomfort, which may not align perfectly with objective clinical measures.

Key Studies & References Management of Allergic and Nonallergic Rhinitis: Summary (Agency for Healthcare Research and Quality - AHRQ)

Common questions about Колдакт (FAQ)

Q: What is Колдакт used for?

A: Колдакт is used to help temporarily relieve symptoms associated with the common cold, such as nasal congestion, runny nose, sneezing, and fever. Its use is focused on symptom management.

Q: How should I take Колдакт?

A: Specific instructions on how to use any medication, including dosing and frequency, should always be obtained directly from the product's official packaging, regulatory label, or a healthcare professional. You should not use any medication without reviewing the official guidance.

Q: Who should not take Колдакт?

A: Колдакт is typically contraindicated (should not be used) in individuals with known hypersensitivity to the drug's components. Based on the ingredients, caution or avoidance is often advised for people with severe high blood pressure (hypertension), certain heart conditions, or severe thyroid issues. Your doctor can determine if this medication is appropriate for your specific health profile.

Q: Can children use Колдакт?

A: The suitability and approved dosage for children depend on the specific formulation and the national regulatory guidelines for over-the-counter cold medications. Always consult the product label or a healthcare provider to confirm if the medication is safe for a child and what the proper dose is.

Q: Does Колдакт cause drowsiness?

A: One of the active components in some formulations of Колдакт may potentially cause drowsiness. Patients are generally advised to be aware of this possibility and to exercise caution when driving or operating heavy machinery until they know how the medication affects them.

How to Store and Dispose of Колдакт?

The storage and disposal of this medicine must adhere strictly to the conditions specified in official regulatory labeling to ensure product quality and integrity.

Storage Requirement	Official Condition
Temperature	Store below 25 C or 30 C (ambient conditions); do not refrigerate or freeze.
Protection	Keep the capsules protected from both light and moisture.
Container	Store in the original outer carton and primary packaging until the time of use.
Safety	Keep the medicine strictly out of the sight and reach of children.

These storage constraints are necessary to maintain the stability of the sustained-release capsule and its active ingredients until the expiration date. For disposal, unused or expired medicine must not be placed in household trash or poured down a sink. Instead, follow local regulations by utilizing authorized drug take-back programs.